Work

Allogeneic Hematopoietic Cell Transplantation (HCT) Yields Lower Relapse Rates but No Overall Survival Benefit for Adults with Acute Lymphoblastic Leukemia (ALL) in First Minimal Residual Disease (MRD)-Negative Remission

Year: 2015

Type: article

Abstract: Allogeneic HCT is used commonly in adults with ALL. MRD is an accepted prognostic factor in ALL. Being MRD-negative (MRDNeg) overcomes age and cytogenetics (CG; Bassan, Blood, 2009), and it is predictive of outcome without (No) HCT and prior to myeloablative (MAC) and reduced-intensity HCT (RIC). However, comparisons of these treatments in this favorable-risk subgroup are limited. We sought to examine outcomes with these 3 approaches exclusively in pts in first MRDNeg remission (MRDNeg CR1).

Source: Transplantation and Cellular Therapy

Authors: Ryan D. Cassaday, D. Alan Potts, Philip A. Stevenson, Merav Bar, George Georges, Andrei R. Shustov, Mohamed L. Sorror, Brent L. Wood, Colleen Delaney, Kristine C. Doney, Rainer F. Storb, Brenda M. Sandmaier

Institutions: University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

OpenAlex ID: W2042815385

FWCI:

Cites:

Cited by:

Related to: 10